Fairfield, Bush & Co’s NovoCure NVCR Stock Holding History

Fairfield, Bush & Co’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5	Closed	–	–	342
2022 Q2	$0	Buy	+5	New	+$377	﹤0.01%	488

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fairfield, Bush & Co's NVCR Position: Q3 2022 in Review

Fairfield, Bush & Co sold out of NovoCure (NVCR) in Q3 2022, closing a stake of 5 shares.

Fairfield, Bush & Co first reported a position in NVCR in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 303 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

Fairfield, Bush & Co reported no remaining NovoCure position as of Q3 2022 after selling out during the quarter.
Fairfield, Bush & Co sold 5 NovoCure shares in Q3 2022.
Fairfield, Bush & Co first reported a position in NovoCure in Q2 2022 and held it in 1 quarter.
Fairfield, Bush & Co's NovoCure position peaked at $0 in Q2 2022.
303 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on Fairfield, Bush & Co's 13F filing for Q3 2022, filed 7 Nov 2022.